<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702816</url>
  </required_header>
  <id_info>
    <org_study_id>15-888</org_study_id>
    <nct_id>NCT03702816</nct_id>
  </id_info>
  <brief_title>The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)</brief_title>
  <official_title>The Relationship Between Neuropsychological Testing and MRI, PET and Blood Biomarkers in Neurodegenerative Disease (COBRE - Project 1): AIM 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aaron Ritter, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jeffrey Cummings, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jessica Caldwell, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The complex pathological cascades leading to both Alzheimer's disease (AD) and Parkinson's
      disease (PD) involve, at various points, inflammation. Since inflammation is a treatable
      symptom, understanding how and when it impacts the brain, and where specifically in the
      brain, would offer important guidance in the development of new treatments, sorely needed in
      both diseases.

      Microglia play an important anti-inflammatory role, and produce a substance, mitochondrial
      translocator protein (TSPO), whose presence can be used as a marker of regional inflammation.
      GE180 is a newly developed PET ligand which binds to TSPO and hence can be used in imaging
      studies to analyze regional inflammation in living patients. In prior studies it has shown
      regional specificity in multiple sclerosis and brain injury. In the current study, the
      investigators will be using GE180 to analyze regional and global inflammation in the brains
      of patients with AD and PD at two time points.

      The results of the current study will provide enriched understanding of inflammation in these
      conditions, and potentially provide preliminary data to inform design of future
      interventional trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will involve a cohort that is currently being established at the Cleveland Clinic
      Lou Ruvo Center for Brain Health. The cohort has been established under the NIH Center of
      Biomedical Research Excellence (COBRE) grant and involves annual collection of detailed
      neuropsychological testing and biomarkers (blood and neuroimaging) from all participants
      annually. Data are filed in a registry (CNTN). Participants include healthy controls,
      participants with PD (with and without mild cognitive impairment (MCI)) and patients with MCI
      (with or without positive florbetapir scan, which demonstrates underlying AD changes likely
      causing the cognitive impairment) and patients with AD. For the current study, we will focus
      on patients with MCI with associated underlying AD or PD.

      Participants will undergo GE180 PET. This will occur twice, once at baseline and one year
      after initial testing. The approach to PET data collection and analysis will be similar to
      work done previously with an earlier generation ligand (Edison et al., 2008) and to other
      work with this tracer (Fan et al., 2016). Participants will complete ECGs and have their
      vitals taken prior to and immediately following injections. Briefly, the ligand will be
      injected, there will be a 90 minute uptake period, and scan acquisition will commence for 30
      minutes, and will be collected in list mode and rebinned into 18 time frames post
      acquisition.

      The total duration of the study visit will be around 4 hours, and the participants will
      receive $50 compensation for the visit.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will receive two Flutriciclamide (18F-GE180) PET scans. One will be done at baseline (Y1) and one will be done approximately 12 months later (Y2).</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Linear Regression Model Assessing Cognitive Performance and Regional Microglial Activation</measure>
    <time_frame>Baseline</time_frame>
    <description>We will use a linear regression model to assess whether regional microglial activation is predictive of cognitive performance in domains of memory, visuospatial function, language, and executive functioning. These differing units of measurement collected through neuropsychological evaluation will be aggregated into one model in order to assess the correlations between regional activation and cognitive performance in any different domains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Repeated Measures Analyses to Asses Change in Microglial Activation Over Time</measure>
    <time_frame>Baseline (Year 1) compared to Year 2</time_frame>
    <description>We will use repeated measures analyses to asses whether there is a significant change in microglial activation between year 1 scan and year 2 scan. We will then assess if this change in microglial activation over this time period relates to changes in cognitive measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Linear Regression Model Assessing Cognitive Performance and Global Microglial Activation</measure>
    <time_frame>Baseline</time_frame>
    <description>We will use a linear regression model to assess whether global microglial activation is predictive of overall cognitive performance (as assessed with scores on the Dementia Rating Scale (DRS) and Montreal Cognitive Assessment (MoCA)).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Parkinson Disease</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alzheimer's Disease (N=20)
GE180 PET Scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parkinson's Disease (N=20; 10 with PD-MCI, 10 PD with no cognitive impairment)
GE180 PET Scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control Group (N=10)
GE180 PET Scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild Cognitive Impairment (N=20; 10 florbetapir positive, 10 florbetapir negative)
GE180 PET Scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>GE180 PET Scan</intervention_name>
    <description>GE180 PET Scan</description>
    <arm_group_label>AD</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>MCI</arm_group_label>
    <arm_group_label>PD</arm_group_label>
    <other_name>Flutriciclamide (F18-GE180)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be enrolled in CNTN

          2. Aged 55 to 90

          3. Available study partners

          4. Willing and able to participate in longitudinal follow-up study

          5. For MCI patients, fit criteria based in Movement Disorders Task Force or NIA

        Exclusion Criteria:

          1. Significant neurological disorders other than AD or PD;

          2. Unstable medical conditions

          3. History of major psychiatric diseases

          4. MRI evidence of infarction or other focal lesion or multiple lacunes

          5. Clinically significant abnormalities in B12 or TSH

          6. Identified as having a common polymorphism (rs6971) in the TSPO gene which has been
             shown to reduce binding affinity of tracers similar to GE180. This testing will be
             done as part of their CNTN participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron R Ritter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, Lamb BT, Bhaskar K. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015 Jun;138(Pt 6):1738-55. doi: 10.1093/brain/awv081. Epub 2015 Mar 31.</citation>
    <PMID>25833819</PMID>
  </reference>
  <reference>
    <citation>Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med. 2006 Aug 31;38(4):333-47. Review.</citation>
    <PMID>16953112</PMID>
  </reference>
  <reference>
    <citation>Ji K, Miyauchi J, Tsirka SE. Microglia: an active player in the regulation of synaptic activity. Neural Plast. 2013;2013:627325. doi: 10.1155/2013/627325. Epub 2013 Nov 3. Review.</citation>
    <PMID>24303218</PMID>
  </reference>
  <reference>
    <citation>Benavides J, Fage D, Carter C, Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 1987 Sep 22;421(1-2):167-72.</citation>
    <PMID>2891401</PMID>
  </reference>
  <reference>
    <citation>Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, Trigg W, Brooks DJ, Hinz R, Edison P. Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. J Nucl Med. 2016 Nov;57(11):1753-1759. Epub 2016 Jun 3.</citation>
    <PMID>27261523</PMID>
  </reference>
  <reference>
    <citation>Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2304-19. doi: 10.1007/s00259-008-0908-9. Epub 2008 Oct 1. Review.</citation>
    <PMID>18828015</PMID>
  </reference>
  <reference>
    <citation>Boutin H, Murray K, Pradillo J, Maroy R, Smigova A, Gerhard A, Jones PA, Trigg W. 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):503-11. doi: 10.1007/s00259-014-2939-8. Epub 2014 Oct 29.</citation>
    <PMID>25351507</PMID>
  </reference>
  <reference>
    <citation>Liu B, Le KX, Park MA, Wang S, Belanger AP, Dubey S, Frost JL, Holton P, Reiser V, Jones PA, Trigg W, Di Carli MF, Lemere CA. In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice. J Neurosci. 2015 Nov 25;35(47):15716-30. doi: 10.1523/JNEUROSCI.0996-15.2015.</citation>
    <PMID>26609163</PMID>
  </reference>
  <reference>
    <citation>Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement. 2016 Jun;12(6):719-32. doi: 10.1016/j.jalz.2016.02.010. Epub 2016 May 11. Review.</citation>
    <PMID>27179961</PMID>
  </reference>
  <reference>
    <citation>Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, Hammers A, Tai YF, Fox N, Kennedy A, Rossor M, Brooks DJ. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008 Dec;32(3):412-9. doi: 10.1016/j.nbd.2008.08.001. Epub 2008 Aug 15.</citation>
    <PMID>18786637</PMID>
  </reference>
  <reference>
    <citation>Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5. doi: 10.1038/jcbfm.2011.147. Epub 2011 Oct 19.</citation>
    <PMID>22008728</PMID>
  </reference>
  <reference>
    <citation>Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, Wakuda T, Sugihara G, Takebayashi K, Suda S, Iwata Y, Ueki T, Tsuchiya KJ, Suzuki K, Nakamura K, Ouchi Y. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):343-51. doi: 10.1007/s00259-010-1612-0. Epub 2010 Sep 16.</citation>
    <PMID>20844871</PMID>
  </reference>
  <reference>
    <citation>Dickens AM, Vainio S, Marjamäki P, Johansson J, Lehtiniemi P, Rokka J, Rinne J, Solin O, Haaparanta-Solin M, Jones PA, Trigg W, Anthony DC, Airas L. Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med. 2014 Mar;55(3):466-72. doi: 10.2967/jnumed.113.125625. Epub 2014 Feb 10.</citation>
    <PMID>24516258</PMID>
  </reference>
  <reference>
    <citation>Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, Veronese M. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans. 2015 Aug;43(4):586-92. doi: 10.1042/BST20150058. Epub 2015 Aug 3. Review.</citation>
    <PMID>26551697</PMID>
  </reference>
  <reference>
    <citation>Rizzo G, Veronese M, Tonietto M, Zanotti-Fregonara P, Turkheimer FE, Bertoldo A. Kinetic modeling without accounting for the vascular component impairs the quantification of [(11)C]PBR28 brain PET data. J Cereb Blood Flow Metab. 2014 Jun;34(6):1060-9. doi: 10.1038/jcbfm.2014.55. Epub 2014 Mar 26.</citation>
    <PMID>24667911</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Aaron Ritter, MD</investigator_full_name>
    <investigator_title>Director of Clinical Trials</investigator_title>
  </responsible_party>
  <keyword>neuroinflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

